Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet(Brigham and Women's Hospital), Louis O’Dea(Akebia Therapeutics (United States)), Victoria J. Bartlett(Akebia Therapeutics (United States)), Amparo L. Figueroa(Akebia Therapeutics (United States)), Joseph L. Witztum(University of California, San Diego), Richard S. Geary(Ionis Pharmaceuticals (United States)), Seth J. Baum(Boca Raton Regional Hospital), P Piscitelli(Akebia Therapeutics (United States)), Ewa Karwatowska‐Prokopczuk(Akebia Therapeutics (United States)), Joyce Kingsbury(Akebia Therapeutics (United States)), Sotirios Tsimikas(University of California San Diego), Eunju Hurh(Akebia Therapeutics (United States)), W. S. Singleton(Ionis Pharmaceuticals (United States))
Cited by 276
Related Papers
Role of oxidized low density lipoprotein in atherogenesis.
|Journal of Clinical Investigation|1991|2.7k
A comprehensive classification system for lipids
|Journal of Lipid Research|2005|1.8k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k
Hypertriglyceridemic Waist
|Circulation|2000|934